<DOC>
	<DOCNO>NCT02119247</DOCNO>
	<brief_summary>The purpose study compare systemic availability CHF 6001 single dose CHF 6001 administer use multi-dose NEXThaler® device single-dose capsule inhaler Aerolizer® . CHF 6001 antinflammatory drug development Chronic obstructive pulmonary disease ( COPD ) therapy . The drug present dry powder inhalation deliver inhaler device . Previous study conduct use single-dose capsule inhaler ( Aerolizer® ) device . For subsequent clinical study novel multi-dose NEXThaler® device use .</brief_summary>
	<brief_title>Study Investigate Pharmacokinetics CHF 6001 DPI Administered Via Nexthaler® Device Capsule Oral Inhalation Via Aerolizer® Device</brief_title>
	<detailed_description>This Open-label , randomize , 2-way cross-over , Phase I study . The study conduct 1 single european site . The main scope study compare systemic availability CHF 6001 single dose CHF 6001 DPI administer use multi-dose reservoir NEXThaler® device single-dose capsule Aerolizer® device .</detailed_description>
	<criteria>1 . Subject 's write informed consent obtain prior studyrelated procedure 2 . Able understand study procedure , risk involve ability train use device correctly 3 . Able generate sufficient PIF 4 . Male female subject age 18 55 year inclusive 5 . Body mass index ( BMI ) within range 18 30 kg/m2 inclusive 6 . Non exsmokers smoke &lt; 5 pack year 7 . Good physical mental status 8 . Lung function within normal limit 9 . Results laboratory test within normal range 10. adequate contraception 1 . Blood donation ( equal 450 ml ) blood loss le 8 week inhalation study medication 2 . Pregnant lactate woman 3 . Positive HIV1 HIV2 serology 4 . Positive result Hepatitis serology indicate acute chronic Hepatitis B Hepatitis C 5 . Unsuitable vein repeat venipuncture 6 . History substance abuse drug abuse within 12 month prior screen visit positive urine drug screen 7 . Subjects positive urine test cotinine screen randomization 8 . Clinically relevant abnormal laboratory value screen suggest unknown disease require clinical investigation 9 . Clinically relevant uncontrolled hepatic , gastrointestinal , endocrine , metabolic , neurologic , psychiatric disorder may interfere successful completion protocol 10 . Subjects clinically significant cardiovascular condition accord investigator 's judgment 11 . An abnormal 12lead ECG 12 . Subjects whose electrocardiogram ( 12lead ECG ) show QTcF &gt; 450 m male QTcF &gt; 470 m female 13 . Diastolic Blood Pressure &gt; 90 mmHg and/or Systolic Blood Pressure &gt; 140 mmHg 14 . Participation another clinical trial investigation drug receive less 8 week prior screen 15 . History hypersensitivity excipients contain formulation use trial 16 . Any drug treatment , include prescribed OTC medicine well vitamin , homeopathic remedy etc , take 14 day ( 2 month enzymeinducing enzymeinhibiting drug e.g. , glucocorticoid , phenobarbital ) screen visit likely receive treatment end study procedure exception occasional paracetamol ( maximum 2 g per day maximum 10 g per 14 day mild nonexcluding condition ) , hormonal contraceptive hormonal replacement treatment postmenopausal woman 17 . Treatment within previous 3 month screen visit likely receive treatment end study procedure last treatment period biologic drug drug know welldefined potential hepatotoxicity ( e.g . isoniazide , nimesulide , ketoconazole ) 18 . Subjects refuse respect require study restriction relate alcohol , xanthine , grapefruit , food water intake strenuous activity 19 . Heavy caffeine drinker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>systemic availability , pharmacokinetics , COPD</keyword>
</DOC>